MCLA-158

· Merus B.V.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MCLA-158, covering 2025-01-29 to 2025-01-29. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]